Literature DB >> 4577623

Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma.

P J Fialkow, E Klein, G Klein, P Clifford, S Singh.   

Abstract

Two independent marker systems, G-6-PD isoenzymes and cell membrane-associated IgM, were used to trace the cellular origin of Burkitt lymphoma. Application of the G-6-PD system is dependent upon the fact that, in accordance with inactivity of one X chromosome in each somatic cell, females heterozygous for the usual B gene (Gd(B)) at the X-linked G-6-PD locus and the variant allele Gd(A) (or Gd(A-)) have two types of cells. Gd(B) is active in one cell population, which consequently produces B type enzyme; in the other population Gd(A) is active, producing the variant A enzyme. Therefore, tumors with a clonal origin in a Gd(B)/Gd(A) heterozygote should exhibit only one enzyme type (B or A) whereas those with multicellular origin may show both A and B enzymes. Utilization of the immunoglobulin system is based upon the supposition that in lymphoid neoplasms with clonal origin either all or none of the tumor cells should have surface-associated IgM and kappa-reactivities. 33 of 34 relatively homogeneous (with respect to content of neoplastic cells) individual Burkitt tumors from 19 G-6-PD heterozygotes had single enzyme phenotypes. Similarly, of 95 tumors tested, 92 consisted essentially of IgM(+) or (-) cells. Two neoplasms could not be definitely classified and one tumor had two cell populations. These data suggest a clonal origin for most Burkitt tumors, but the one neoplasm with a double G-6-PD phenotype (A/B) and the one tumor that had two populations of cells with respect to surface IgM, could have originated from multiple cells. G-6-PD was determined in each of two tumors from seven heterozygotes and in all cases both tumors had the same single enzyme phenotype. Surface-associated IgM was tested in four tumors from one patient, three from another, and in two neoplasms from 11 patients. With one exception, all tumors from the same patient were concordant with respect to IgM. These findings suggest that the entire disease has a clonal origin, i.e., it emerges at one focus and then spreads to other parts of the body. Cells from 36 recurrent neoplasms were typed for G-6-PD (in heterozygotes) and/or IgM. In one previously reported patient, initial and recurrent tumors were discordant for G-6-PD. Two other patients had IgM phenotypes in recurrences that were discordant with those found in their initial tumors. Phenotypes from three of nine relapses which occurred after 5 mo were discordant for G-6-PD or IgM but no discordance was detected among 27 earlier recurrences. Thus, some "late" recurrences may be due to emergence of "new" maligant cell lines whereas most early relapses are due to reemergence of the original malignant clones. The probable unicellular origin of Burkitt lymphoma and the findings in tumor recurrences are discussed in terms of the disease's putative viral etiology.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4577623      PMCID: PMC2180537          DOI: 10.1084/jem.138.1.89

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  DEMONSTRATION OF TWO POPULATIONS OF CELLS IN THE HUMAN FEMALE HETEROZYGOUS FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE VARIANTS.

Authors:  R G DAVIDSON; H M NITOWSKY; B CHILDS
Journal:  Proc Natl Acad Sci U S A       Date:  1963-09       Impact factor: 11.205

2.  The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker.

Authors:  E BEUTLER; M YEH; V F FAIRBANKS
Journal:  Proc Natl Acad Sci U S A       Date:  1962-01-15       Impact factor: 11.205

3.  Immunological characterization of lymphocytes in lymphoproliferative diseases. Restriction of classes, subclasses, and Gm allotypes of membrane-bound Ig.

Authors:  S S Froland; J B Natvig; P Stavem
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

4.  Immunoglobulins on the surface of neoplastic lymphocytes.

Authors:  A C Aisenberg; K J Bloch
Journal:  N Engl J Med       Date:  1972-08-10       Impact factor: 91.245

5.  Second malignant clone underlying a Burkitt-tumor exacerbation.

Authors:  P J Fialkow; G Klein; P Clifford
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

6.  Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival.

Authors:  P Clifford; S Singh; J Stjernswärd; G Klein
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

Review 7.  Use of genetic markers to study cellular origin and development of tumors in human females.

Authors:  P J Fialkow
Journal:  Adv Cancer Res       Date:  1972       Impact factor: 6.242

8.  [Membrane monoclonal immunoglobulins in chronic lymphoid leukemia].

Authors:  J L Preud'homme; M Klein; P Verroust; M Seligmann
Journal:  Rev Eur Etud Clin Biol       Date:  1971-12

9.  Isolation and partial characterization of lymphocyte surface immunoglobulins.

Authors:  J J Marchalonis; R E Cone; J L Atwell
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

10.  Class, subclass, and allelic exclusion of membrane-bound Ig of human B lymphocytes.

Authors:  S S Fröland; J B Natvig
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  27 in total

1.  Evidence for monoclonal proliferation in prolymphocytic leukemia of T-cell orgin. A cytogenetic and Quantitative immunoautoradiographic analysis.

Authors:  E Thiel; M Bauchinger; H Rodt; D Huhn; H Theml; S Thierfelder
Journal:  Blut       Date:  1977-12

2.  Epstein-Barr virus growth-transformed cells are converted to malignancy following transfection of a 1.3-kb CATR1 antisense construct independent of a change in the level of c-myc expression followed by a 8;14 chromosomal translocation.

Authors:  D Li; X L Sun; B Casto; J Fang; K Theil; R Glaser; G Milo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 3.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

4.  Control mechanisms in infectious mononucleosis.

Authors:  A M Denman; B K Pelton
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

5.  Human genetic markers as tracers of tumour histogenesis.

Authors:  P J Fialkow
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1974

6.  Characterization of non-Hodgkin's lymphomas using multiple cell markers. Immunologic, morphologic, and cytochemical studies of 72 cases.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

7.  Immunologic surface markers in non-Hodgkin's lymphomas.

Authors:  J Cossman; B Schnitzer; M J Deegan
Journal:  Am J Pathol       Date:  1977-04       Impact factor: 4.307

8.  Surface receptors on human haematopoietic cell lines.

Authors:  C Huber; C Sundström; K Nilsson; H Wigzell
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

9.  Humoral immune response in Epstein-Barr virus infections. I. Elevated serum concentration of the IgG1 subclass in infectious mononucleosis and nasopharyngeal carcinoma.

Authors:  W P Kaschka; R Hilgers; F Skvaril
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

10.  Persistence of human adenovirus 5 in human cord blood lymphoblastoid cell lines transformed by Epstein-Barr virus.

Authors:  N Faucon; C Desgranges
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.